There was a time, not too long ago, when a diagnosis of metastatic melanoma left little hope, with life expectancy measured in just a few months. Today, that paradigm has been ...
Daraxonrasib received FDA breakthrough therapy designation for metastatic PDAC with KRAS G12 mutations, expediting its development. The designation is based on promising phase 1 trial results, with ...
About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead ...
Many cancers can often be treated successfully when detected early. Surgery, radiation and chemotherapy are all powerful tools to remove or destroy tumors in their original location. However, when ...
Ampligen and Imfinzi combination therapy demonstrated clinical activity for patients with metastatic pancreatic cancer. A combination immunotherapy approach using Ampligen (rintatolimod) and Imfinzi ...